Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Jackie Blacklaw"'
Autor:
R. A. Gillham, M. J. Brodie, G. Forrest, D. Connelly, S. M. Walker, P. J. W. Mckee, Jackie Blacklaw
Publikováno v:
British Journal of Clinical Pharmacology. 37:27-32
1. The effect of carbamazepine (CBZ), sodium valproate (VPA) and phenytoin (PHT) on the pharmacokinetics of oxcarbazepine (OXC) was explored in three groups of 12 epileptic patients taking one of these drug as monotherapy. 2. Each patient took a sing
Publikováno v:
Epilepsia. 40(2)
Summary: Purpose: To study the effects of antiepileptic drugs (AEDs) on sex hormone levels and sexual activity in a group of men attending a hospital-based epilepsy clinic. Methods: One hundred eighteen men being treated with AED therapy, 32 with epi
Publikováno v:
Epilepsia. 38(10)
Summary: Purpose: To examine certain aspects of sexual behaviour and attitudes in a group of women with epilepsy using a validated questionnaire (Sexuality Experience Scales), and effects of antiepileptic drugs (AEDs) on sex hormone binding globulin
Autor:
Tracey Jones, John Paul Leach, Martin J. Brodie, Alan Richens, Jackie Blacklaw, Virginia Jamieson
Publikováno v:
Epilepsia. 37(11)
Summary: Purpose: We wished to determine mutual interaction of two drugs with active metabolism: remacemide, hydrochloride and carbamazepine (CBZ). Methods: A randomized, double-blind, placebo-controlled cross-over study of add-on remacemide hydrochl
Epilepsy arises from an imbalance of inhibitory and excitatory influences in the brain. Vigabatrin (VIG) decreases the breakdown of the inhibitory neurotransmitter gamma-aminobutyric acid, whereas lamotrigine (LTG) reduces presynaptic excitatory amin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3137c003d2ad140e0f84f513f1eaf33
https://europepmc.org/articles/PMC1073074/
https://europepmc.org/articles/PMC1073074/
Publikováno v:
Epilepsia. 34(5)
A double-blind, randomized, cross-over study of additional vigabatrin (gamma-vinyl-GABA, VGB, 1.0 g twice daily for 6 weeks, followed by 1.5 g twice daily for 6 weeks) and matched placebo was undertaken in 24 patients with refractory epilepsy. Ninete